about
Campbell De Morgan's 'Observations on cancer', and their relevance todayBCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy controlThe continuing challenges of leprosyCo-administration of IL-1+IL-6+TNF-α with Mycobacterium tuberculosis infected macrophages vaccine induces better protective T cell memory than BCGProspects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?The Delta fbpA mutant derived from Mycobacterium tuberculosis H37Rv has an enhanced susceptibility to intracellular antimicrobial oxidative mechanisms, undergoes limited phagosome maturation and activates macrophages and dendritic cells.Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning.A critical role for CD8 T cells in a nonhuman primate model of tuberculosis.CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis.Development and initial testing of messages to encourage tuberculosis testing and treatment among Bacille Calmette-Guerin (BCG) vaccinated persons.Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens.The immunology of tuberculosis: from bench to bedside.Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter?Immune gene networks of mycobacterial vaccine-elicited cellular responses and immunity.Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infectionProposing low-similarity peptide vaccines against Mycobacterium tuberculosisVaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis.Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guérin (BCG) vaccines from different sources, Kazakhstan.Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis.Helicobacter hepaticus infection in BALB/c mice abolishes subunit-vaccine-induced protection against M. tuberculosis.The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.Risk factors for Buruli ulcer, Benin.Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis.Tuberculosis vaccine development: research, regulatory and clinical strategies.Tuberculous meningitis: diagnosis and treatment overview.IL-17RA in Non-Hematopoietic Cells Controls CXCL-1 and 5 Critical to Recruit Neutrophils to the Lung of Mycobacteria-Infected Mice during the Adaptive Immune ResponsePoor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis.Challenges of Childhood TB/HIV Management in Malawi.American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States.Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and controlChildhood pulmonary tuberculosis: old wisdom and new challenges.Roles of Mucosal Immunity against Mycobacterium tuberculosis InfectionCombination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.Helminthes could influence the outcome of vaccines against TB in the tropics.Characterization of novel multiantigenic vaccine candidates with pan-HLA coverage against Mycobacterium tuberculosis.Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone.Diagnostic and management challenges for childhood tuberculosis in the era of HIV.A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice.
P2860
Q22241584-263DF108-CA6B-4504-BF1B-0DDFC9673813Q22305924-D4B99936-C386-4389-B76C-52F1086C8291Q24545809-90388979-13C3-4044-A612-29FD3B45729CQ27437712-9924D0D2-4B06-4036-B829-3F79656F72B6Q28083377-9E8647A4-16C3-4FDB-A3CE-4BA53F419A14Q33318121-8F85BE59-FB81-4374-B398-E8346397D2F7Q33383676-F23A217F-415E-4B6A-B78C-24415B413F11Q33432697-7F7F6385-E5CF-41B3-91D4-459BA2BC2345Q33521270-4D106E16-9952-41B5-BFA1-E315DF3C7405Q33668251-F4B42B77-D028-482C-A164-FAA66C619B73Q33769431-793DE57F-7714-4EB1-903C-0346898F7693Q33777367-6DD3DC25-267E-41B3-BD7F-CD2EAD6AC9E9Q33811658-2DF57FDF-C1CA-43BC-A8C5-7672DDB0AC15Q33914191-922779E3-1832-42D2-B6C2-5AA94B85CFD8Q33919973-E87A27A7-F8A4-45E4-8360-333B6A28D29AQ33946585-048AE667-72DF-407D-92AC-8F9A8ED7BBA7Q33961091-40ACE302-69FA-4D77-AEF2-75B892E76854Q34111604-A743A25A-69E0-4F3B-A80C-CAF7AD9D41E6Q34199914-5BE06D2D-8EE7-48A7-9A6B-59076D64907BQ34491796-6E56AF2F-2FF1-4779-B263-FACEA9B30112Q35573126-D5351FB1-79EA-4491-ABE4-BF67455D8485Q35689134-BB3AF132-2CBE-45F2-935C-531C6CE1463DQ35805701-F33A2AA3-FE36-4134-8EFF-578D086D2C02Q35839810-D56F5A43-A87F-4402-93CC-AD28522A4FD2Q35873788-E5B42F4C-8265-472C-9F30-5BC76B993B4CQ35910242-E481E394-1048-4B6D-B1F5-7A31E48CF129Q35922094-D2FF7C88-3521-45F3-B6A8-9CD822E439F6Q35927959-C79BEDA2-03F0-4AC0-A386-86E16CAB8058Q35939235-51456635-D782-443A-84ED-C1A1CC4BF955Q36297088-DBF904E8-86E1-4AD3-969C-345BFF817F22Q36361918-303DCB89-8F9C-42CC-98E9-E891F69543AEQ36399322-7BED062B-0F3A-4AB8-A30A-C79D838B5A8FQ36417953-13539E0A-8F4F-45E9-A20C-9F76456DDC77Q36576750-DBAB7FE9-E5E2-4C4D-8DAA-D8F977D1C733Q36590688-52141E16-9936-4BD2-AAE4-73973D2F0B4EQ36668540-1D5BD892-9DCD-4A59-BC30-E484E0401CC8Q36672533-C2CB8F49-2618-40F2-A0E9-18A60BE2ACEFQ36877242-4624B2C2-755D-40EA-B30C-FEA7BF9AC658Q36950010-014E61B7-19DE-4BEE-985F-CFA8AE687336Q36950022-D1743E04-8869-4787-B1F7-2223FACB3B6F
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
BCG: the challenge continues.
@ast
BCG: the challenge continues.
@en
BCG: the challenge continues.
@nl
type
label
BCG: the challenge continues.
@ast
BCG: the challenge continues.
@en
BCG: the challenge continues.
@nl
prefLabel
BCG: the challenge continues.
@ast
BCG: the challenge continues.
@en
BCG: the challenge continues.
@nl
P1476
BCG: the challenge continues.
@en
P2093
P304
P356
10.1080/003655401300077144
P577
2001-01-01T00:00:00Z